Evidence map›Paper›PMID 37507160›Full record

ArticleAdvances in microbial physiology2023

Making a chink in their armor: Current and next-generation antimicrobial strategies against the bacterial cell envelope.

Nikol Kadeřábková, Ayesha J S Mahmood, R Christopher D Furniss, Despoina A I Mavridou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in microbial physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nikol KadeřábkováDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, United States.
Ayesha J S MahmoodDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, United States.
R Christopher D FurnissMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial College London, London, United Kingdom.
Despoina A I MavridouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, United States; John Ring LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, TX, United States. Electronic address: despoina.mavridou@austin.utexas.edu.
The University of Texas at Austin · USImperial College London · GB

Funding

The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteriaR01AI158753 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI Despoina Mavridou · 2022 to 2026
$1.9M
NIAID NIH HHS R01 AI158753
6 · The paper itself

Abstract

Gram-negative bacteria are uniquely equipped to defeat antibiotics. Their outermost layer, the cell envelope, is a natural permeability barrier that contains an array of resistance proteins capable of neutralizing most existing antimicrobials. As a result, its presence creates a major obstacle for the treatment of resistant infections and for the development of new antibiotics. Despite this seemingly impenetrable armor, in-depth understanding of the cell envelope, including structural, functional and systems biology insights, has promoted efforts to target it that can ultimately lead to the generation of new antibacterial therapies. In this article, we broadly overview the biology of the cell envelope and highlight attempts and successes in generating inhibitors that impair its function or biogenesis. We argue that the very structure that has hampered antibiotic discovery for decades has untapped potential for the design of novel next-generation therapeutics against bacterial pathogens.

Indexed as

Anti-Bacterial AgentsGram-Negative BacteriaCell MembraneCell WallAnti-Bacterial AgentsAntibiotic adjuvantAntibiotic discoveryAntibiotic targetAntimicrobial resistanceBacterial membraneCell envelopeExtracytoplasmic proteinGram-negative bacteriaLipopolysaccharidePeptidoglycan

Identifiers

PMID37507160
PMCPMC10517717
OpenAlexW4382289130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.